ALLISON MOORE: Open Payments
NPI 1770643843 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,283 in 61 payments from 9 companies in 2025. Trend: 2023 $1,421 · 2024 $1,124 · 2025 $1,283
Food & beverage: $1,283
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 24 | $414 |
| ABBVIE INC. | 12 | $277 |
| Madrigal Pharmaceuticals | 6 | $155 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $138 |
| Ipsen Biopharmaceuticals, Inc | 4 | $101 |
| Intercept Pharmaceuticals, Inc. | 4 | $98 |
| ORPHALAN INC | 2 | $53 |
| Intra-Sana Laboratories | 1 | $25 |
| Eton Pharmaceuticals, Inc. | 1 | $23 |
Products named: MAVYRET, REZDIFFRA, XIFAXAN, IQIRVO, OCALIVA, CUVRIOR, RELTONE 200 MG, ALKINDI.
Industry payments across TX — which companies pay providers there.
